Pneumonia Therapeutics Market Synopsis

Pneumonia Therapeutics Market Size Was Valued at USD 14.49 Billion in 2023, and is Projected to Reach USD 30.20 Billion by 2032, Growing at a CAGR of 8.50% From 2024-2032.

The Pneumonia Therapeutics Market is segmented into a wide variety of products for medical treatment of pneumonia, which is a dangerous lung infection resulting from bacterial, viral or fungal causes. This market also encompasses different therapeutic categories including antibiotics and antivirals, antifungal, and supportive care which seeks to reduce symptoms, enhance lung function, and avoid progression to complications. As the advancements in the healthcare system is made and people turning toward various investments in different respiratory diseases outcomes that pneumonia has on the global population, the market has shifted toward value-added products such as monoclonal antibodies and vaccines necessary to push forward additional improved results in treatment and decreasing the number of hospitalizations around the world. Pneumonia incidence persists and poses a threat to patients with other disorders such as children and the elderly, hence the increased need for adequate therapeutics.

• The pneumonia therapeutics market has undergone a lot of transformation over the recent past due to growing consciousness of respiratory diseases as well as breakthrough health products. Pneumonia is still a major public health issue which has significant effects on population, especially on the people with some heath problems, including elderly patients. market is quite diverse with therapeutics such as Antibiotics, Antifungal agents and fairly adjunct therapeutical options which are aimed at relieving symptoms in order to improve recovery. Pneumonia has been on the rise as the population ages, and increasing incidences of chronic respiratory diseases have created the market for effective therapeutic agents.
• Identified key market trends show a strong portfolio of new therapeutics with continued research interest on synthesizing new antibiotics due to the growing public health threat of antibiotic resistance. While drugs like monoclonal antibodies and vaccines are emerging trends, we see trends like personalized medicines for chronic diseases are now on the rise. Also, the use of telemedicine to provide and support digital health solutions has ensured patients have better access to healthcare as well as increase case management hence has increased effectiveness of treatment. Regionally, the North American and European markets have large shares as the countries in these regions boast of highly developed health facilities, high health costs and good health policies. However, the two markets in Asia-Pacific and Latin America are expected to experience high growth due to increasing health care expenditure and enhance access to health care.
• Pneumonia therapeutics industry competition landscape is gradually escalating, from strategic partnership, merger & acquisitions and marketing campaigns perspective. The same trend has an impact on market strategies as a focus on pathology and real-life performance as well as the focus on patients’ needs led to companies offering care solutions that go beyond pharmacotherapy. In this context, the pneumonia therapeutics market is expected to experience significant growth in the future, mainly due to the constant long-term development and research, increasing number of treatment approaches, and constant contribution to the development of new methods that improve the quality of the fight against pneumonia.

Pneumonia Therapeutics Market Trend Analysis

Addressing the Growing Demand for Innovative Treatments

• With the rise in the number of cases of pneumonia and the people most at risk of getting the diseases like the elderly and the immunocompromised the have become susceptible to this disease there is increased demand in the therapeutic products. Pneumonia continues to be a major public health problem globally and more so amongst these vulnerable groups of people. These include demographic changes including aging, high prevalence of chronic respiratory diseases, increased occurrence of healthcare-associated pneumonia. These challenges raise the imperative for health-care systems to search for a more effective approach to manage individual patient needs. This in turn, is reinforced by the growing problem of multidrug-resistant bacteria, where new treatment plans and new antibiotics and other adjuvants are required to combat these resistant forms of bacteria.
• Technological developments are particularly defining the change of pneumonia pharmaceuticals. The fairly recent innovation of tailor-made drugs, including the spectacular monoclonal antibodies and new formulations of antibiotics, provide benefit with relatively fewer side effects. These therapies can eventually home in on the causes of pneumonia as compared to the general targeted composites, which ay enhance the treatment procedures. The researchers are also looking into other auxiliary treatments, immunomodulators for stimulating operations of a human body for combating infections. This approach of care delivery as not only a way to enhance patient conditions but also as a strategy to control the increasing problem of antimicrobial resistance due to bacteria becoming resistant to broad-spectrum antibiotics. Since, there are numerous study conducted in this line indicating that therapeutics for pneumonia has a potential of growing especially due to the introduction of safer and more effective options.

The Impact of Telemedicine and Combination Therapies

• The respective innovations of telemedicine and home cases monitoring have greatly redefined the management of patients with pneumonia and the general Entire Medical industry.. Health care providers are able to perform online consultations, as it is possible to diagnose an illness and begin with treatment immediately not requiring a face to face meeting. This capability is particularly relevant for patients who may have a difficulty accessing more conventional facilities and spaces, for example due to disability or geographical isolation. COVID-19 has propelled this change, emphasising the need for systems that may continue healthcare service provision while reducing vulnerability to viral diseases. Therefore, most healthcare organizations are using telehealth technologies that help monitor patient’s signs and compliance with prescribed treatment regimes regarding pneumonia management.• Besides development of the telemedicine the treatment of pneumonia with the use of combined therapies is developing.tment, making healthcare more accessible and efficient. Digital platforms enable healthcare providers to conduct virtual consultations, allowing for timely diagnosis and immediate initiation of treatment without the need for in-person visits. This capability is especially crucial for patients who may face barriers to accessing traditional healthcare settings, such as those with mobility issues or living in remote areas. The COVID-19 pandemic has accelerated this trend, highlighting the necessity of adaptable healthcare delivery systems that can continue to provide care while minimizing the risk of exposure to infectious diseases. As a result, many healthcare systems are investing in telehealth technologies that facilitate real-time monitoring of patient symptoms and treatment adherence, leading to better overall management of pneumonia cases.
• In addition to advancements in telemedicine, there is a growing trend toward combination therapies in pneumonia treatment. In view of the causative agents, clinical manifestations, and risk factors of pneumonia, such therapies offer multiple routes of intervention, which are also challenging infections. The use of supplements with the main treatment that is antibiotics for instance corticosteroids or immunomodulators will always increase the chances of a successful treatment and thus decrease the phenomena of treatment failure. This multipronged approach not only works towards enhancing the cabotage of patients, it way also goes a long way in preventing antimicrobial resistance because could lead to the shortening of the dosage and frequency of antibiotics. As more studies actively discover these differentiated formulations of the medicines, the market for pneumonia therapeutics will continue to expand and diversify to allow for optimal conditions for innovative drug development that addresses the current issues and future patient requirements.

Pneumonia Therapeutics Market Segment Analysis:

Pneumonia Therapeutics Market Segmented based on By Infection Type, By Drug Class, By Type and By End-Users.

By Infection Type, Hospital-acquired Pneumonia (HAP) segment is expected to dominate the market during the forecast period

• Healthcare-associated pneumonia or hospital acquired pneumonia (HAP) pose a major challenge in management especially considering the increasing concern for multidrug resistant organism.. Hospitals and patients may include: Long stay, use of specific products like endotracheal tube and exposure to other patients with underlying diseases that weaken their immune systems. These conditions contribute to development of other infections which are likely to complicate treatment regimens. Thus, there is a serious problem and an important clinical challenge for healthcare providers to find suitable antimicrobial treatments that act against such bacteria but do not create conditions for the emergence of new, more resistant strains. The antibiotic resistance profiles of different strains continue to evolve, and constant monitoring, and robust diagnostic tools for early identification are mandatory to ensure that the right therapeutic management is promptly instituted.• In response to HAP, there is need for fully integrated and intensified treatment approach.ents, largely due to the prevalence of multidrug-resistant pathogens. Patients in hospitals are often at increased risk for HAP because of factors such as prolonged hospitalization, invasive procedures like intubation, and the presence of comorbidities that compromise their immune systems. These conditions create a conducive environment for opportunistic infections, complicating treatment protocols. Consequently, healthcare providers face the urgent need to identify effective antimicrobial therapies that target resistant bacteria while minimizing the risk of further resistance development. The emergence of antibiotic-resistant strains necessitates ongoing surveillance and rapid diagnostic capabilities, enabling timely intervention and appropriate therapy adjustments.
• To effectively manage HAP, a comprehensive and aggressive treatment strategy is essential. This often encompasses the prescription of medications that work against all forms of bacteria and fungi along with individual targeted drugs inclusive of those suggested by susceptibility results to enable clinicians effectively target pathogens. Moreover, other combinant therapies including oxygen and mechanical ventilation as well as respiratory physiotherapy are essential in management of patients’ respiratory condition and subsequent results. The nature of HAP management process show why it is necessary to involve many personnel such as physicians, nurses and respiratory therapists to make sure that patients with HAP get the best health service. Finally, as the delivery of health care systems undergoes changes the emphasis will necessarily need to be placed on the developing novel treatment approaches as well as infection control measures to decrease the occurrence and mortality of HAP in clinical settings.

By End-Users, Hospitals segment held the largest share in 2023

• Intensive care is in most cases managed in special wards, especially the hospitals in those patients with severe or complicated pneumonia.. These environments present the clinician with difficulties of assessing and managing patient with mechanically compromised health that may be at the risk of fatal outcomes due to delayed or slow treatments. Pneumonia has been identified on time through the use of imaging and diagnostic equipment in the modern hospitals which are demand driven due to high quality care on patients. Further, extensive treatment plans have taken their place in the hospitals that integrate a combination of most recent therapies that match the types of pneumonia with the particular patients. It is standard practice to utilize broad-spectrum antimicrobial agents together with range of other adjuvant therapies – such as corticosteroids – to enhance patient outcomes and shorten the length of stay in the hospital.• In addition, the recent years have seen different hospitals pay considerable attention to the infection control measures due to high rates of antibiotic resistance that have made it even difficult to treat pneumonia.he challenge of treating patients with potentially life-threatening conditions, necessitating rapid and effective interventions. This demand for high-quality care has prompted hospitals to adopt advanced technologies, including state-of-the-art imaging and diagnostic tools like chest X-rays and CT scans, which aid in the timely identification of pneumonia. Additionally, hospitals are implementing robust treatment protocols that incorporate evidence-based practices, ensuring that patients receive the most effective therapies tailored to their specific types of pneumonia. Such protocols often include the use of broad-spectrum antibiotics, alongside adjunct therapies like corticosteroids, to improve patient outcomes and reduce the duration of hospital stays.
• Furthermore, hospitals are increasingly focusing on infection control measures to combat the rising rates of antibiotic resistance, which complicate pneumonia treatment. Antibiotic use for example through antimicrobial stewardship programs are still being offered to help avoid further ushering in of resistance patterns. This systems approach is not only more effective in promoting patient safety but also in improving how resources are handled within delivery of hospital services. As the healthcare industry develops, the hospitals are also looking for new ways to expand and integrate telemedicine for explaining and following up on the further treatment plans to the patient who have been discharged. Through direct investment a health facility gets the expertise and innovative equipment to tackle this disease with a resultant increased survival ratio and better health of patients.

Pneumonia Therapeutics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• The pneumonia therapeutics market in North America continues to be well developed due to sound healthcare systems and generous research grants.. The availability of modern healthcare infrastructure and use of high technologies support creation and implementation of new approaches to therapy. Pneumonia remains a common disease in this region in both adults and children, an area in which there is a clear need for adequate treatment options. The recent widespread understanding of the disease, along with educational campaigns, has stimulated the growth of vaccination and prescription of the antibiotics, which creates the demand for the market.• In addition, a variety of prolific pharmaceutical industries based in North America also fuels the growth of this market.and substantial research funding. The advanced medical facilities and access to cutting-edge technologies facilitate the development and deployment of innovative treatment options. This region witnesses a high prevalence of pneumonia among both adults and children, emphasizing the critical need for effective therapeutic solutions. The increasing awareness of pneumonia, coupled with educational initiatives, has led to a notable rise in vaccination rates and antibiotic prescriptions, further driving market demand.
• Moreover, the presence of major pharmaceutical companies in North America plays a pivotal role in the market's growth. These firms spend huge Resources In research and development to come up with new therapies that supplement existing treatment methods to deliver improved results for the patient. COOP also fosters appropriate industry and healthcare provider interaction for creating improved treatment protocols necessary for more efficient handling of pneumonia patients. Since healthcare policies of North American countries are shifting to preventive care and evidence-based treatment, the pneumonia therapeutics market will continue to has good prospects.

Active Key Players in the Pneumonia Therapeutics Market

• AstraZeneca (U.K.)
• Lilly (U.S.)
• Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Hikma Pharmaceuticals PLC (U.K.)
• Cipla Inc. (India)
• Other Key Players

Key Industry Developments in the Pneumonia Therapeutics Market:

• In May, 2024 Zai Lab and Innoviva Specialty Therapeutics received NMPA approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) in China treating hospital-acquired and ventilator-associated pneumonia caused by the Acinetobacter Baumannii-Calcoaceticus Complex.
• In Spetember, 2023, Phaxiam Therapeutics SA launched a new preclinical research program aimed at Klebsiella pneumoniae, a bacteria that causes serious infections and is known for its great resistance to antibiotics.
• In May, 2023 the U.S. Food and Drug Administration has authorized a new drug Xacduro produced by Innoviva Specialty Therapeutics, which is used to treat hospital-acquired pneumonia caused by a difficult-to-treat bacteria.
• In November, 2023 The COMBINE (Collaboration for the Prevention and Treatment of MDR Bacterial Infections) initiative of the Innovative Medicines Initiative is creating a standardized in vivo pneumonia model to test small-molecule antibiotics.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Pneumonia Therapeutics Market by Infection Type
 4.1 Pneumonia Therapeutics Market Snapshot and Growth Engine
 4.2 Pneumonia Therapeutics Market Overview
 4.3 Hospital-acquired Pneumonia (HAP)
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Hospital-acquired Pneumonia (HAP): Geographic Segmentation Analysis
 4.4 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP): Geographic Segmentation Analysis

Chapter 5: Pneumonia Therapeutics Market by Drug Class
 5.1 Pneumonia Therapeutics Market Snapshot and Growth Engine
 5.2 Pneumonia Therapeutics Market Overview
 5.3 Antibacterial Drugs
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Antibacterial Drugs: Geographic Segmentation Analysis
 5.4 Antiviral Drugs and Antifungal Drugs
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Antiviral Drugs and Antifungal Drugs: Geographic Segmentation Analysis

Chapter 6: Pneumonia Therapeutics Market by Type
 6.1 Pneumonia Therapeutics Market Snapshot and Growth Engine
 6.2 Pneumonia Therapeutics Market Overview
 6.3 Drugs
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Drugs: Geographic Segmentation Analysis
 6.4 Preventive Vaccines and Oxygen Therapy
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Preventive Vaccines and Oxygen Therapy: Geographic Segmentation Analysis

Chapter 7: Pneumonia Therapeutics Market by End-Users
 7.1 Pneumonia Therapeutics Market Snapshot and Growth Engine
 7.2 Pneumonia Therapeutics Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Homecare
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Homecare: Geographic Segmentation Analysis
 7.5 Specialty Clinics and Others
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Specialty Clinics and Others: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Pneumonia Therapeutics Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 ASTRAZENECA
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 LILLY
 8.4 HOFFMANN-LA ROCHE
 8.5 MYLAN
 8.6 TEVA PHARMACEUTICAL INDUSTRIES
 8.7 SANOFI
 8.8 NOVARTIS
 8.9 SUN PHARMACEUTICAL INDUSTRIES
 8.10 AUROBINDO PHARMA
 8.11 LUPIN
 8.12 MERCK
 8.13 PFIZER
 8.14 GSK
 8.15 HIKMA PHARMACEUTICALS
 8.16 CIPLA
 8.17 OTHER KEY PLAYERS

Chapter 9: Global Pneumonia Therapeutics Market By Region
 9.1 Overview
 9.2. North America Pneumonia Therapeutics Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Infection Type
  9.2.4.1 Hospital-acquired Pneumonia (HAP)
  9.2.4.2 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  9.2.5 Historic and Forecasted Market Size By Drug Class
  9.2.5.1 Antibacterial Drugs
  9.2.5.2 Antiviral Drugs and Antifungal Drugs
  9.2.6 Historic and Forecasted Market Size By Type
  9.2.6.1 Drugs
  9.2.6.2 Preventive Vaccines and Oxygen Therapy
  9.2.7 Historic and Forecasted Market Size By End-Users
  9.2.7.1 Hospitals
  9.2.7.2 Homecare
  9.2.7.3 Specialty Clinics and Others
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Pneumonia Therapeutics Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Infection Type
  9.3.4.1 Hospital-acquired Pneumonia (HAP)
  9.3.4.2 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  9.3.5 Historic and Forecasted Market Size By Drug Class
  9.3.5.1 Antibacterial Drugs
  9.3.5.2 Antiviral Drugs and Antifungal Drugs
  9.3.6 Historic and Forecasted Market Size By Type
  9.3.6.1 Drugs
  9.3.6.2 Preventive Vaccines and Oxygen Therapy
  9.3.7 Historic and Forecasted Market Size By End-Users
  9.3.7.1 Hospitals
  9.3.7.2 Homecare
  9.3.7.3 Specialty Clinics and Others
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Pneumonia Therapeutics Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Infection Type
  9.4.4.1 Hospital-acquired Pneumonia (HAP)
  9.4.4.2 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  9.4.5 Historic and Forecasted Market Size By Drug Class
  9.4.5.1 Antibacterial Drugs
  9.4.5.2 Antiviral Drugs and Antifungal Drugs
  9.4.6 Historic and Forecasted Market Size By Type
  9.4.6.1 Drugs
  9.4.6.2 Preventive Vaccines and Oxygen Therapy
  9.4.7 Historic and Forecasted Market Size By End-Users
  9.4.7.1 Hospitals
  9.4.7.2 Homecare
  9.4.7.3 Specialty Clinics and Others
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Pneumonia Therapeutics Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Infection Type
  9.5.4.1 Hospital-acquired Pneumonia (HAP)
  9.5.4.2 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  9.5.5 Historic and Forecasted Market Size By Drug Class
  9.5.5.1 Antibacterial Drugs
  9.5.5.2 Antiviral Drugs and Antifungal Drugs
  9.5.6 Historic and Forecasted Market Size By Type
  9.5.6.1 Drugs
  9.5.6.2 Preventive Vaccines and Oxygen Therapy
  9.5.7 Historic and Forecasted Market Size By End-Users
  9.5.7.1 Hospitals
  9.5.7.2 Homecare
  9.5.7.3 Specialty Clinics and Others
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Pneumonia Therapeutics Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Infection Type
  9.6.4.1 Hospital-acquired Pneumonia (HAP)
  9.6.4.2 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  9.6.5 Historic and Forecasted Market Size By Drug Class
  9.6.5.1 Antibacterial Drugs
  9.6.5.2 Antiviral Drugs and Antifungal Drugs
  9.6.6 Historic and Forecasted Market Size By Type
  9.6.6.1 Drugs
  9.6.6.2 Preventive Vaccines and Oxygen Therapy
  9.6.7 Historic and Forecasted Market Size By End-Users
  9.6.7.1 Hospitals
  9.6.7.2 Homecare
  9.6.7.3 Specialty Clinics and Others
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Pneumonia Therapeutics Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Infection Type
  9.7.4.1 Hospital-acquired Pneumonia (HAP)
  9.7.4.2 Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP)
  9.7.5 Historic and Forecasted Market Size By Drug Class
  9.7.5.1 Antibacterial Drugs
  9.7.5.2 Antiviral Drugs and Antifungal Drugs
  9.7.6 Historic and Forecasted Market Size By Type
  9.7.6.1 Drugs
  9.7.6.2 Preventive Vaccines and Oxygen Therapy
  9.7.7 Historic and Forecasted Market Size By End-Users
  9.7.7.1 Hospitals
  9.7.7.2 Homecare
  9.7.7.3 Specialty Clinics and Others
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research